Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in Chronic Spontaneous Urticaria (PEARL-1)
NCT03580369Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of ligelizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Oct 2018; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03580369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580369.